デフォルト表紙
市場調査レポート
商品コード
1022069

嚢胞性線維症治療薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)

Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 145 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
嚢胞性線維症治療薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
出版日: 2021年08月02日
発行: IMARC Services Private Limited
ページ情報: 英文 145 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

嚢胞性線維症治療薬の世界市場は、2015年から2020年にかけて力強い成長を示し、2021年から2026年の間に約10%のCAGRで市場規模が拡大すると予想されています。

嚢胞性線維症(CF)は、希少な進行性の遺伝性疾患で、消化管や呼吸器系でナトリウムや塩化物が異常に移動することが特徴です。この疾患は、肺、膵臓、腸、肝臓などに粘性のある分泌物を発生させる原因となります。CFの管理と治療には、物理療法、遺伝子治療、理学療法、栄養補給が行われます。これと並行して、遺伝子治療や膵臓酵素サプリメント、粘液溶解剤、気管支拡張剤、嚢胞性線維症膜貫通コンダクタンス調節因子(CFTR)調節剤などの医薬品も、細胞のインターアクトームを標的とし、症状の改善を目的として使用されます。これらの薬剤は、経口または吸入により患者に投与されます。

世界的な嚢胞性線維症の罹患率の上昇と、この疾患の診断技術の向上が、市場成長を促進する主な要因となっています。さらに、CFTR(嚢胞性線維症膜貫通型コンダクタンス)モジュレーターが治療法として広く普及していることも、市場成長を後押ししています。CFTRは、肺などの細胞内膜を通過する水や塩化物の流れを調節し、体内で機能不全に陥ったタンパク質を修正するように構成されています。さらに、個別化された薬物療法、分子補綴、効能を向上させた革新的な薬剤の開発など、様々な技術の進歩もまた成長促進要因なっています。医療費の増加、健康意識の高まり、嚢胞性線維症の治療法に関する意識の向上などの要因も、市場をさらに押し上げる見通しです。

当レポートは、世界の嚢胞性線維症治療薬市場について調査しており、業界動向、市場予測、医薬品クラス・薬物分子タイプ・投与経路・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。また、 COVID-19の不確実性を念頭に置いて、さまざまな最終用途産業に対するパンデミックの直接的および間接的な影響を継続的に追跡および評価しています 。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の嚢胞性線維症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 医薬品クラス別の市場セグメンテーション

  • 膵臓酵素サプリメント
  • 粘液溶解薬
  • 気管支拡張薬
  • CFTRモジュレーター
  • 抗生物質
  • その他

第7章 薬物分子タイプ別の市場セグメンテーション

  • 小分子薬
  • 生物製剤

第8章 投与経路別の市場セグメンテーション

  • 経口薬
  • 吸入薬

第9章 エンドユーザー別市場セグメンテーション

  • 病院
  • クリニック
  • その他

第10章 地域別の市場セグメンテーション

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場セグメンテーション

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格指標

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2020
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2020
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2020
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million US$), 2021-2026
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million US$), 2021-2026
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players
目次
Product Code: SR1020E135_Report

The global cystic fibrosis therapeutics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further.

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc. Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the drug molecule type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cystic fibrosis therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis